nach oben

Breast Cancer Research

Erschienen in:

01.06.2003 | Review

Inflammatory breast cancer: Relationship between growth factor signaling and motility in aggressive cancers

verfasst von: Kenneth L van Golen

Erschienen in: Breast Cancer Research | Ausgabe 3/2003

Einloggen, um Zugang zu erhalten

Abstract

A variety of phenotypic characteristics are required for a cancer cell to successfully complete the metastatic cascade. Acquisition of a motile and invasive phenotype is one requirement for a cell to become metastatically competent. The Rho (Ras homology) GTPases are a subfamily of small GTP-binding proteins, which are related to the Ras oncogene. All aspects of cellular motility and invasion are controlled by the Rho GTPases and are closely linked to signals from the extracellular environment, particularly in response to growth factors. Dysregulation of Rho activation through aberrant growth-factor signaling, loss of function of key Rho-regulatory proteins or overexpression of Rho mRNA could result in increased Rho activity and cellular motility. Therefore, the importance of the Rho GTPases in the progression of aggressive cancers, is becoming more appreciated.

Kleer CG, van Golen KL, Merajver SD: Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res. 2000, 2: 423-429. 10.1186/bcr89.CrossRefPubMedPubMedCentral

Breast Cancer Facts and Figures 2001–2002. American Cancer Society, Atlanta, GA. 2002, [http://www.cancer.org/downloads/STT/BrCaFF2001.pdf]

van Golen KL, Davies S, Wu ZF, Wang Y, Bucana CD, Root H, Chandrasekharappa S, Strawderman M, Ethier SP, Merajver SD: A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res. 1999, 5: 2511-2519.PubMed

van Golen KL, Wu ZF, Qiao XT, Bao LW, Mearajver SD: RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res. 2000, 60: 5832-5838.PubMed

Sahai E, Marshall CJ: Rho-GTPases and cancer. Nat Rev Cancer. 2002, 2: 133-142. 10.1038/nrc725.CrossRefPubMed

Fritz G, Just I, Kaina B: Rho GTPases are over-expressed in human tumors. Int J Cancer. 1999, 81: 682-687. 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B.CrossRefPubMed

Ridley AJ: Rho GTPases and cell migration. J Cell Sci. 2001, 114: 2713-2722.PubMed

Kjoller L, Hall A: Signaling to Rho GTPases. Exp Cell Res. 1999, 253: 166-179. 10.1006/excr.1999.4674.CrossRefPubMed

Ren XD, Kiosses WB, Schwartz MA: Regulation of the small GTP-binding protein Rho by cell adhesion and the cytoskeleton. EMBO J. 1999, 18: 578-585. 10.1093/emboj/18.3.578.CrossRefPubMedPubMedCentral

10.

Lin R, Cerione RA, Manor D: Specific contributions of the small GTPases Rho, Rac, and Cdc42 to Dbl transformation. J Biol Chem. 1999, 274: 23633-23641. 10.1074/jbc.274.33.23633.CrossRefPubMed

11.

Symons M, Settleman J: Rho family GTPases: more than simple switches. Trends Cell Biol. 2000, 10: 415-419. 10.1016/S0962-8924(00)01832-8.CrossRefPubMed

12.

Geyer M, Wittinghofer A: GEFs, GAPs, GDIs and effectors: taking a closer (3D) look at the regulation of Ras-related GTP-binding proteins. Curr Opin Struct Biol. 1997, 7: 786-792. 10.1016/S0959-440X(97)80147-9.CrossRefPubMed

13.

Roof RW, Haskell MD, Dukes BD, Sherman N, Kinter M, Parsons SJ: Phosphotyrosine (p-Tyr)-dependent and -independent mechanisms of p190 RhoGAP-p120 RasGAP interaction: Tyr 1105 of p190, a substrate for c-Src, is the sole p-Tyr mediator of complex formation. Mol Cell Biol. 1998, 18: 7052-7063.CrossRefPubMedPubMedCentral

14.

Moores SL, Selfors LM, Fredericks J, Breit T, Fujikawa K, Alt FW, Brugge JS, Swat W: Vav family proteins couple to diverse cell surface receptors. Mol Cell Biol. 2000, 20: 6364-6373. 10.1128/MCB.20.17.6364-6373.2000.CrossRefPubMedPubMedCentral

15.

Bustelo XR: Vav proteins, adaptors and cell signaling. Oncogene. 2001, 20: 6372-6381. 10.1038/sj.onc.1204780.CrossRefPubMed

16.

Sahai E, Marshall CJ: ROCK and mDia have opposing effects on adherens junctions downstream of Rho. Nat Cell Biol. 2002, 4: 408-415. 10.1038/ncb796.CrossRefPubMed

17.

Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T, Narumiya S: An essential part for Rho-assoicated kinase in the transcellular invasion of tumor cells. Nat Med. 1999, 5: 221-225. 10.1038/5587.CrossRefPubMed

18.

Bishop AL, Hall A: Rho GTPases and their effector proteins. Biochem J. 2000, 348 (pt 2): 241-255. 10.1042/0264-6021:3480241.CrossRefPubMedPubMedCentral

19.

Tikoo A, Czekay S, Viars C, White S, Heath JK, Arden K, Maruta H: p190-A, a human tumor suppressor gene, maps to the chromosomal region 19q13.3 that is reportedly deleted in some gliomas. Gene. 2000, 257: 23-31. 10.1016/S0378-1119(00)00387-5.CrossRefPubMed

20.

Sachdev P, Jiang YX, Li W, Miki T, Maruta H, Nur-E-Kamal MS, Wang LH: Differential requirement for Rho family GTPases in an oncogenic insulin-like growth factor-I receptor-induced cell transformation. J Biol Chem. 2001, 276: 26461-26471. 10.1074/jbc.M010995200.CrossRefPubMed

21.

Lee RJ, Albanese C, Fu M, D'Amico M, Lin B, Watanabe G, Haines GK, Siegel PM, Hung MC, Yarden Y, Horowitz JM, Muller WJ, Pestell RG: Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol. 2000, 20: 672-683. 10.1128/MCB.20.2.672-683.2000.CrossRefPubMedPubMedCentral

22.

Bernards R, Weinberg RA: A progression puzzle. Nature. 2002, 418: 823-10.1038/418823a.CrossRefPubMed

23.

Ren XD, Kiosses WB, Sieg DJ, Otey CA, Schlaepfer DD, Schwartz MA: Focal adhesion kinase suppresses Rho activity to promote focal adhesion turnover. J Cell Sci. 2000, 113: 3673-3678.PubMed

24.

Guvakova MA, Surmacz E: The activated insulin-like growth factor I repeptor induces depolarization in beast epithelial cells charaterized by actin filament disassembly and tyrosine dephosphorylation of FAK, Cas, and paxillin. Exp Cell Res. 1999, 251: 244-255. 10.1006/excr.1999.4566.CrossRefPubMed

25.

Chen BH, Tzen JTC, Bresnick AR, Chen HC: Role of Rho-associated kinase and myosin light chain kinase in morphologic and migratory defects of focal adhesion kinase-null cells. J Biol Chem. 2002, 277: 33857-33863. 10.1074/jbc.M204429200.CrossRefPubMed

26.

Guvakova MA, Boettiger D, Adams JC: Induction of fascin spikes in breast cancer cells by activation of the insulin-like growth factor-I receptor. Int J Biochem Cell Biol. 2002, 34: 685-698. 10.1016/S1357-2725(01)00160-1.CrossRefPubMed

27.

Guvakova MA, Adams JC, Boettiger D: Functional role of α-actinin, PI 3-kinase and MEK 1/2 in insulin-like growth factor I receptor kinase regulated motility of human breast carcinoma cells. J Cell Sci. 2002, 115: 4149-4165. 10.1242/jcs.00104.CrossRefPubMed

28.

Sander EE, ten Klooster JP, van Delft S, van der Kammen RA, Collard JG: Rac downregulates Rho activity: reciprocal balance between both GTPases determines cellular morphology and migratory behavior. J Cell Biol. 1999, 147: 1009-1027. 10.1083/jcb.147.5.1009.CrossRefPubMedPubMedCentral

29.

Adams JC, Schwartz MA: Stimulation of fascin spikes by thrombospondin-1 is mediated by the GTPases Rac and Cdc42. J Cell Biol. 2000, 150: 807-822. 10.1083/jcb.150.4.807.CrossRefPubMedPubMedCentral

30.

Pennisi PA, Barr V, Nunez NP, Stannard B, Le Roith D: Reduced expression of insulin-like growth factor I receptors in MCF-7 breast cancer cells leads to a more metastatic phenotype. Cancer Res. 2002, 62: 6529-6537.PubMed

31.

Meyer GE, Shelden E, Kim B, Feldman EL: Insulin-like growth factor I stimulates motility in human neuroblastoma cells. Oncogene. 2001, 20: 7542-7550. 10.1038/sj.onc.1204927.CrossRefPubMed

32.

Tanno S, Tanno S, Mitsuuchi Y, Altomare DA, Xiao GH, Testa JR: AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res. 2001, 61: 589-593.PubMed

33.

Lopez T, Hanahan D: Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell. 2002, 1: 339-353. 10.1016/S1535-6108(02)00055-7.CrossRefPubMed

34.

Jackson JG, Zhang X, Yoneda T, Yee D: Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines. Oncogene. 2001, 20: 7318-7325. 10.1038/sj.onc.1204920.CrossRefPubMed

35.

Zhang X, Yee D: Insulin-like growth factor binding protein-1 (IGFBP-1) inhibits breast cancer cell motility. Cancer Res. 2002, 62: 4369-4375.PubMed

36.

Kleer CG, van Golen KL, Zhang Y, Wu ZF, Rubin MA, Merajver SD: WISP3 is a novel tumor suppressor gene of inflammatory breast cancer. Oncogene. 2002, 21: 3172-3180. 10.1038/sj.onc.1205462.CrossRefPubMed

37.

Lemoine NR, Hughes CM, Barton CM, Poulsom R, Jeffery RE, Kloppel G, Hall PA, Gullick WJ: The epidermal growth factor receptor in human pancreatic cancer. J Pathol. 1992, 166: 7-12.CrossRefPubMed

38.

Kleer CG, van Golen KL, Zhang Y, Wu ZF, Rubin MA, Merajver SD: Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. Am J Pathol. 2002, 160: 579-584.CrossRefPubMedPubMedCentral

39.

Bouzahzah B, Albanese C, Ahmed F, Pixley F, Lisanti MP, Segall JD, Condeelis J, Joyce D, Minden A, Der CJ, Chan A, Symons M, Pestell RG: Rho family GTPases regulate mammary epithelium cell growth and metastasis through distinguishable pathways. Mol Med. 2001, 7: 816-830.PubMedPubMedCentral

40.

Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H, Nakamura H: Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. Cancer Res. 2001, 61: 4885-4891.PubMed

41.

Wang Z, Tung PS, Moran MF: Association of p120 ras GAP with endocytic components and colocalization with epidermal growth factor (EGF) receptor in response to EGF stimulation. Cell Growth Differ. 1996, 7: 123-133.PubMed

Titel: Inflammatory breast cancer: Relationship between growth factor signaling and motility in aggressive cancers
verfasst von: Kenneth L van Golen
Publikationsdatum: 01.06.2003
Verlag: BioMed Central
Erschienen in: Breast Cancer Research / Ausgabe 3/2003
Elektronische ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr598

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Inflammatory breast cancer: Relationship between growth factor signaling and motility in aggressive cancers

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2003

Introducing Viewpoints – Breast Cancer Research'snew style literature appraisal service

Elevated mammaglobin (h-MAM) expression in breast cancer is associated with clinical and biological features defining a less aggressive tumour phenotype

Detection of hepatocyte growth factor/scatter factor receptor (c-Met) in axillary drainage after operations for breast cancer using reverse transcriptase–polymerase chain reaction

Host microenvironment in breast cancer development: Extracellular matrix–stromal cell contribution to neoplastic phenotype of epithelial cells in the breast

Breast cancer-induced angiogenesis: multiple mechanisms and the role of the microenvironment

The future of cytotoxic therapy: selective cytotoxicity based on biology is the key

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie